JP2010522718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522718A5 JP2010522718A5 JP2010500272A JP2010500272A JP2010522718A5 JP 2010522718 A5 JP2010522718 A5 JP 2010522718A5 JP 2010500272 A JP2010500272 A JP 2010500272A JP 2010500272 A JP2010500272 A JP 2010500272A JP 2010522718 A5 JP2010522718 A5 JP 2010522718A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- purin
- pyrazol
- phenyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- -1 benzo [1,3] dioxolyl Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 102000004257 Potassium Channel Human genes 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- DVQOPNIPUIOXHU-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 DVQOPNIPUIOXHU-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 108020001213 potassium channel Proteins 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- LAKYIPSTOCBIGH-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-9-(2-methoxyethyl)-n-phenylpurin-6-amine Chemical compound N1=C(N2C(=CC(C)=N2)C)N=C2N(CCOC)C=NC2=C1NC1=CC=CC=C1 LAKYIPSTOCBIGH-UHFFFAOYSA-N 0.000 claims 1
- HPIALDHBJZLANG-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-9-methyl-n-(2-phenylethyl)purin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NCCC=2C=CC=CC=2)=C(N=CN2C)C2=N1 HPIALDHBJZLANG-UHFFFAOYSA-N 0.000 claims 1
- LSDRWHLLIQWLAA-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-9-methyl-n-(4-nitrophenyl)purin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(=CC=2)[N+]([O-])=O)=C(N=CN2C)C2=N1 LSDRWHLLIQWLAA-UHFFFAOYSA-N 0.000 claims 1
- MDHRZOQHXZSEED-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-9-methyl-n-[4-(trifluoromethyl)phenyl]purin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(=CC=2)C(F)(F)F)=C(N=CN2C)C2=N1 MDHRZOQHXZSEED-UHFFFAOYSA-N 0.000 claims 1
- SWQBZPXHGALVPL-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-9-methyl-n-phenylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC=CC=2)=C(N=CN2C)C2=N1 SWQBZPXHGALVPL-UHFFFAOYSA-N 0.000 claims 1
- SFNDTYYCHFPNPJ-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-9-methyl-n-pyridin-4-ylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CN=CC=2)=C(N=CN2C)C2=N1 SFNDTYYCHFPNPJ-UHFFFAOYSA-N 0.000 claims 1
- FCHDAFWIYTYUTH-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n-(4-fluorophenyl)-9-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(F)=CC=2)=C(N=CN2C)C2=N1 FCHDAFWIYTYUTH-UHFFFAOYSA-N 0.000 claims 1
- OWLCDPPNVHMZOB-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n-phenyl-7h-purin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC=CC=2)=C(N=CN2)C2=N1 OWLCDPPNVHMZOB-UHFFFAOYSA-N 0.000 claims 1
- IVZJKPUNBLSGOH-UHFFFAOYSA-N 2-(4-chloro-3,5-dimethylpyrazol-1-yl)-n-(4-chlorophenyl)-9-methylpurin-6-amine Chemical compound CC1=C(Cl)C(C)=NN1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 IVZJKPUNBLSGOH-UHFFFAOYSA-N 0.000 claims 1
- DXFHHGPKNMVEHR-UHFFFAOYSA-N 2-(4-chloro-3-methylpyrazol-1-yl)-n-(4-chlorophenyl)-9-methylpurin-6-amine Chemical compound C1=C(Cl)C(C)=NN1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 DXFHHGPKNMVEHR-UHFFFAOYSA-N 0.000 claims 1
- MFIDWIAONNDJDA-UHFFFAOYSA-N 2-(5-chloro-3-methylpyrazol-1-yl)-n-(4-chlorophenyl)-9-methylpurin-6-amine Chemical compound N1=C(C)C=C(Cl)N1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 MFIDWIAONNDJDA-UHFFFAOYSA-N 0.000 claims 1
- ANQNLWGEHMNWBN-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)pyrazol-1-yl]-n-(4-chlorophenyl)-9-methylpurin-6-amine Chemical compound N1=C(N2C(=CC(=N2)C(F)(F)F)C(F)(F)F)N=C2N(C)C=NC2=C1NC1=CC=C(Cl)C=C1 ANQNLWGEHMNWBN-UHFFFAOYSA-N 0.000 claims 1
- DXYSJRWJZSLBCS-UHFFFAOYSA-N 4-[[2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-yl]amino]benzonitrile Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(=CC=2)C#N)=C(N=CN2C)C2=N1 DXYSJRWJZSLBCS-UHFFFAOYSA-N 0.000 claims 1
- IMFNNVDXBUGETE-UHFFFAOYSA-N 4-n-[2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-yl]benzene-1,4-diamine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(N)=CC=2)=C(N=CN2C)C2=N1 IMFNNVDXBUGETE-UHFFFAOYSA-N 0.000 claims 1
- PBHFDUNUQBRNOP-UHFFFAOYSA-N 6-(4-chlorophenyl)sulfanyl-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurine Chemical compound N1=C(C)C=C(C)N1C1=NC(SC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 PBHFDUNUQBRNOP-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- KFXJAONTTAGDMF-UHFFFAOYSA-N [2-[6-(4-chloroanilino)-9-methylpurin-2-yl]-5-methylpyrazol-3-yl]methanol Chemical compound N1=C(C)C=C(CO)N1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 KFXJAONTTAGDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000028311 absence seizure Diseases 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- JILGOVQTCFFYRU-UHFFFAOYSA-N ethyl 1-[6-(4-chloroanilino)-9-methylpurin-2-yl]-5-methylpyrazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)C=C(C)N1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 JILGOVQTCFFYRU-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- QTSMUSVACRPCBF-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-2-(3,5-dimethylpyrazol-1-yl)-9-ethylpurin-6-amine Chemical compound N1=C2N(CC)C=NC2=C(NC=2C=C3OCOC3=CC=2)N=C1N1N=C(C)C=C1C QTSMUSVACRPCBF-UHFFFAOYSA-N 0.000 claims 1
- PNDJDUPBDDSPKP-UHFFFAOYSA-N n-(4-bromophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(Br)=CC=2)=C(N=CN2C)C2=N1 PNDJDUPBDDSPKP-UHFFFAOYSA-N 0.000 claims 1
- LBKYEDHQRCYISU-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-diethylpyrazol-1-yl)-9-methylpurin-6-amine Chemical compound N1=C(CC)C=C(CC)N1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 LBKYEDHQRCYISU-UHFFFAOYSA-N 0.000 claims 1
- UGZACSMZFZCJLF-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-7-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N(C)C=N2)C2=N1 UGZACSMZFZCJLF-UHFFFAOYSA-N 0.000 claims 1
- YASLNLYVBLBRCK-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-(2-ethoxyethyl)purin-6-amine Chemical compound N1=C(N2C(=CC(C)=N2)C)N=C2N(CCOCC)C=NC2=C1NC1=CC=C(Cl)C=C1 YASLNLYVBLBRCK-UHFFFAOYSA-N 0.000 claims 1
- OXFVPYHKTKDQIN-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-(2-methylpropyl)purin-6-amine Chemical compound N1=C(N2C(=CC(C)=N2)C)N=C2N(CC(C)C)C=NC2=C1NC1=CC=C(Cl)C=C1 OXFVPYHKTKDQIN-UHFFFAOYSA-N 0.000 claims 1
- AGPUJPIPIGWWIE-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-9-ethylpurin-6-amine Chemical compound N1=C(N2C(=CC(C)=N2)C)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 AGPUJPIPIGWWIE-UHFFFAOYSA-N 0.000 claims 1
- SMRVGEMZXQTXMU-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[3-(furan-2-yl)-5-methylpyrazol-1-yl]-9-methylpurin-6-amine Chemical compound CC1=CC(C=2OC=CC=2)=NN1C(N=C1N(C)C=NC1=1)=NC=1NC1=CC=C(Cl)C=C1 SMRVGEMZXQTXMU-UHFFFAOYSA-N 0.000 claims 1
- WQFMOPBXKIKQIA-UHFFFAOYSA-N n-(4-chlorophenyl)-9-methyl-2-(3,4,5-trimethylpyrazol-1-yl)purin-6-amine Chemical compound CC1=C(C)C(C)=NN1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 WQFMOPBXKIKQIA-UHFFFAOYSA-N 0.000 claims 1
- HKLGPONAUCIKNP-UHFFFAOYSA-N n-(4-chlorophenyl)-9-methyl-2-(5-methyl-3-phenylpyrazol-1-yl)purin-6-amine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN1C(N=C1N(C)C=NC1=1)=NC=1NC1=CC=C(Cl)C=C1 HKLGPONAUCIKNP-UHFFFAOYSA-N 0.000 claims 1
- BQXNAWLDYCXWNU-UHFFFAOYSA-N n-(4-chlorophenyl)-9-methyl-2-[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]purin-6-amine Chemical compound CC1=CC(C(F)(F)F)=NN1C1=NC(NC=2C=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 BQXNAWLDYCXWNU-UHFFFAOYSA-N 0.000 claims 1
- GZTZZLOZIOCJJN-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2N=CC(Cl)=CC=2)=C(N=CN2C)C2=N1 GZTZZLOZIOCJJN-UHFFFAOYSA-N 0.000 claims 1
- GTZYKPFKLYHYCT-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-2-(3,5-dimethylpyrazol-1-yl)-9-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC=2C=NC(Cl)=CC=2)=C(N=CN2C)C2=N1 GTZYKPFKLYHYCT-UHFFFAOYSA-N 0.000 claims 1
- CMYJVPVMHKLTAQ-UHFFFAOYSA-N n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-7-methylpurin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC2CCCCC2)=C(N(C)C=N2)C2=N1 CMYJVPVMHKLTAQ-UHFFFAOYSA-N 0.000 claims 1
- ZVXURWKWHMNVFM-UHFFFAOYSA-N n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-7h-purin-6-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(NC2CCCCC2)=C(N=CN2)C2=N1 ZVXURWKWHMNVFM-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90850307P | 2007-03-28 | 2007-03-28 | |
| DKPA200700482 | 2007-03-28 | ||
| DKPA200700482 | 2007-03-28 | ||
| US60/908,503 | 2007-03-28 | ||
| PCT/EP2008/053648 WO2008116909A1 (en) | 2007-03-28 | 2008-03-27 | Purinyl derivatives and their use as potassium channel modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522718A JP2010522718A (ja) | 2010-07-08 |
| JP2010522718A5 true JP2010522718A5 (https=) | 2011-05-12 |
| JP5703432B2 JP5703432B2 (ja) | 2015-04-22 |
Family
ID=41658005
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500276A Pending JP2010522722A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500273A Pending JP2010522719A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500274A Pending JP2010522720A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500275A Pending JP2010522721A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500272A Active JP5703432B2 (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500276A Pending JP2010522722A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500273A Pending JP2010522719A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500274A Pending JP2010522720A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| JP2010500275A Pending JP2010522721A (ja) | 2007-03-28 | 2008-03-27 | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20100105705A1 (https=) |
| EP (1) | EP2402341B1 (https=) |
| JP (5) | JP2010522722A (https=) |
| KR (1) | KR101564233B1 (https=) |
| CN (1) | CN101646669B (https=) |
| BR (1) | BRPI0808746B8 (https=) |
| NZ (1) | NZ579248A (https=) |
| RU (1) | RU2468026C2 (https=) |
| UA (1) | UA98482C2 (https=) |
| ZA (1) | ZA200905796B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2114916A2 (en) * | 2007-02-02 | 2009-11-11 | NeuroSearch A/S | Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| KR101564233B1 (ko) * | 2007-03-28 | 2015-10-29 | 뉴로서치 에이/에스 | 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도 |
| EP2144911A2 (en) * | 2007-03-28 | 2010-01-20 | NeuroSearch AS | Purinyl derivatives and their use as potassium channel modulators |
| EP2203436A1 (en) | 2007-09-17 | 2010-07-07 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| CA2721851A1 (en) * | 2008-05-30 | 2009-12-03 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
| US8618099B2 (en) * | 2008-09-02 | 2013-12-31 | Ataxion, Inc. | Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| US8268838B2 (en) * | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
| US20110237607A1 (en) * | 2008-09-26 | 2011-09-29 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| US8685987B2 (en) | 2009-04-01 | 2014-04-01 | Ataxion, Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators |
| US8765770B2 (en) | 2009-04-01 | 2014-07-01 | Ataxion, Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| US9475797B2 (en) | 2012-06-26 | 2016-10-25 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| CN105073750A (zh) * | 2013-03-05 | 2015-11-18 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| WO2014135480A1 (en) * | 2013-03-06 | 2014-09-12 | Bayer Pharma Aktiengesellschaft | Substituted thiazolopyrimidines |
| EP3154947B1 (en) * | 2014-06-11 | 2018-03-28 | Bayer CropScience Aktiengesellschaft | Process for preparing 3,5-bis(haloalkyl)pyrazoles via acylation of ketimines |
| CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3528816A4 (en) * | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| SI3571193T1 (sl) | 2017-01-23 | 2022-04-29 | Cadent Therapeutics, Inc. | Modulatorji kalijevega kanalčka |
| FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| CN107698500A (zh) * | 2017-10-17 | 2018-02-16 | 扬子江药业集团四川海蓉药业有限公司 | 一种奈妥匹坦的制备方法 |
| CA3116339A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| CN116178374B (zh) * | 2023-01-13 | 2024-10-08 | 河北医科大学 | 小电导钙激活钾离子通道激动剂及其合成和应用 |
| CN119684293A (zh) * | 2024-11-25 | 2025-03-25 | 山东第一医科大学(山东省医学科学院) | 嘌呤类化合物及其在制备防治脑衰老药物中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3497554B2 (ja) * | 1994-03-25 | 2004-02-16 | 日本臓器製薬株式会社 | 新規プリン誘導体及びその薬学的に許容される塩 |
| AU7296896A (en) * | 1995-11-01 | 1997-05-22 | Novartis Ag | Purine derivatives and processes for their preparation |
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| JP2003531111A (ja) * | 1999-12-17 | 2003-10-21 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | プロトンポンプインヒビター |
| AU2583901A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| CZ294535B6 (cs) * | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
| US7262176B2 (en) * | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
| US20030078232A1 (en) * | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| US20060009642A1 (en) * | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| EP1578722A4 (en) * | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
| US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| AU2003254053A1 (en) * | 2002-07-23 | 2004-02-09 | Smithkline Beecham Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004021979A2 (en) * | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| MXPA06001758A (es) * | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
| US20050239806A1 (en) * | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| GB0407723D0 (en) * | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| FR2876583B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| GB0505219D0 (en) * | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
| US20090036475A1 (en) * | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| EP1863796A1 (en) | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| US7514417B2 (en) * | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| US7419599B2 (en) * | 2005-07-12 | 2008-09-02 | Ge Healthcare Bio-Sciences Ab | Automated packing system and method for chromatography columns |
| EP1966184B1 (en) * | 2005-12-20 | 2010-08-25 | NeuroSearch A/S | Pyridinyl-quinazoline derivatives and their medical use |
| KR20090112732A (ko) * | 2007-01-26 | 2009-10-28 | 아이알엠 엘엘씨 | 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물 |
| EP2114916A2 (en) * | 2007-02-02 | 2009-11-11 | NeuroSearch A/S | Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| KR101564233B1 (ko) * | 2007-03-28 | 2015-10-29 | 뉴로서치 에이/에스 | 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도 |
| EP2144911A2 (en) * | 2007-03-28 | 2010-01-20 | NeuroSearch AS | Purinyl derivatives and their use as potassium channel modulators |
| BRPI0818578A2 (pt) * | 2007-10-17 | 2015-07-21 | Novartis Ag | Derivados de purina como ligantes receptores de adenosina a1 |
| US20110237607A1 (en) * | 2008-09-26 | 2011-09-29 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| US8268838B2 (en) * | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
-
2008
- 2008-03-27 KR KR1020097020281A patent/KR101564233B1/ko active Active
- 2008-03-27 JP JP2010500276A patent/JP2010522722A/ja active Pending
- 2008-03-27 UA UAA200908793A patent/UA98482C2/ru unknown
- 2008-03-27 US US12/593,269 patent/US20100105705A1/en not_active Abandoned
- 2008-03-27 JP JP2010500273A patent/JP2010522719A/ja active Pending
- 2008-03-27 JP JP2010500274A patent/JP2010522720A/ja active Pending
- 2008-03-27 ZA ZA200905796A patent/ZA200905796B/xx unknown
- 2008-03-27 EP EP11182703.6A patent/EP2402341B1/en active Active
- 2008-03-27 BR BRPI0808746A patent/BRPI0808746B8/pt active IP Right Grant
- 2008-03-27 RU RU2009132881/04A patent/RU2468026C2/ru active
- 2008-03-27 JP JP2010500275A patent/JP2010522721A/ja active Pending
- 2008-03-27 CN CN2008800099645A patent/CN101646669B/zh active Active
- 2008-03-27 JP JP2010500272A patent/JP5703432B2/ja active Active
- 2008-03-27 US US12/593,220 patent/US20120004246A1/en not_active Abandoned
- 2008-03-27 NZ NZ579248A patent/NZ579248A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522718A5 (https=) | ||
| RU2009132881A (ru) | Производные пуринила и их применение в качестве модуляторов калиевых каналов | |
| US8580957B2 (en) | Thetrahydroquinolines derivatives as bromodomain inhibitors | |
| JP6121658B2 (ja) | 治療用化合物、及び関連する使用の方法 | |
| TWI771327B (zh) | 新穎化合物 | |
| JP2009519995A5 (https=) | ||
| JP7050759B2 (ja) | 縮合二環式ｓｇｃ刺激剤 | |
| US9271978B2 (en) | Heterocyclic compounds as bromodomain inhibitors | |
| ES2862931T3 (es) | Inhibidores de la catecol O-metil transferasa y su uso en el tratamiento de trastornos psicóticos | |
| US20220356180A1 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| US11944622B2 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
| US10253043B2 (en) | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | |
| US9073929B2 (en) | Aldosterone synthase inhibitors | |
| US11173145B2 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| US20130012511A1 (en) | Soluble guanylate cyclase activators | |
| JP2014522837A (ja) | 治療用化合物としてのキナゾリン及び関連の使用方法 | |
| US9656971B2 (en) | COMT inhibitors | |
| US20120232074A1 (en) | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | |
| JP2021533093A (ja) | モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物 | |
| JP2022500402A5 (https=) | ||
| CN109843884B (zh) | 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 | |
| US20170216257A1 (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| RS59018B1 (sr) | Heteroaromatična jedinjenja i njihova upotreba kao dopamin d1 liganada | |
| JP2010502674A5 (https=) | ||
| JP2008533087A5 (https=) |